Patents by Inventor John Stingl

John Stingl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240191187
    Abstract: Disclosed are media, kits and methods for directed formation of mammary organoids. Embodiments of organoid media may be used to bias/enrich the formation of luminal organoids from isolated mammary epithelial cells. Embodiments of modified organoid media may be used to bias/enrich the formation of mixed lineage organoids from isolated mammary epithelial cells, or to subvert luminal organoids to mixed lineage organoids.
    Type: Application
    Filed: April 14, 2022
    Publication date: June 13, 2024
    Inventors: David ROWBOTHAM, John STINGL
  • Patent number: 7723047
    Abstract: The present invention relates to an improved method that permits the differential isolation of mouse mammary stem cells and colony forming cells (CFCs). The method involves depletion of non-epithelial cells from freshly dissociated mouse mammary tissue by incubation with an antibody composition containing antibodies specific for CD45, Ter119, CD35 and optionally CD140a. After formation of conjugates between the non-epithelial mammary cells and the antibodies specific for CD45, Ter119, CD35 and optionally CD140a, the cell conjugates are removed and the remaining epithelial cells are then incubated with an antibody composition containing antibodies specific for CD24 and CD49f or CD24 and CD14. After formation of conjugates between the epithelial cells and the antibodies specific for CD24 and CD49f or CD24 and CD14, the mouse mammary stem and the luminal-restricted CFC cells can be differentially isolated.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: May 25, 2010
    Assignees: Stemcell Technologies Inc., British Columbia Cancer Agency Branch
    Inventors: John Stingl, Connie J. Eaves
  • Patent number: 7638285
    Abstract: The present invention relates to an improved method that permits the differential isolation of mouse mammary stem cells and colony forming cells (CFCs). The method involves depletion of non-epithelial cells from freshly dissociated mouse mammary tissue by incubation with an antibody composition containing antibodies specific for CD45, Ter119, CD35 and optionally CD140a. After formation of conjugates between the non-epithelial mammary cells and the antibodies specific for CD45, Ter119, CD35 and optionally CD140a, the cell conjugates are removed and the remaining epithelial cells are then incubated with an antibody composition containing antibodies specific for CD24 and CD49f. After formation of conjugates between the epithelial cells and the antibodies specific for CD24 and CD49f, the mouse mammary stem and the luminal-restricted CFC cells can be differentially isolated. The invention also relates to kits for carrying out this method and to the cell preparations prepared by this method.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: December 29, 2009
    Assignees: StemCell Technologies Inc., British Columbia Cancer Agency Branch
    Inventors: John Stingl, Connie J. Eaves
  • Publication number: 20080032402
    Abstract: The present invention relates to an improved method that permits the differential isolation of mouse mammary stem cells and colony forming cells (CFCs). The method involves depletion of non-epithelial cells from freshly dissociated mouse mammary tissue by incubation with an antibody composition containing antibodies specific for CD45, Ter119, CD35 and optionally CD140a. After formation of conjugates between the non-epithelial mammary cells and the antibodies specific for CD45, Ter119, CD35 and optionally CD140a, the cell conjugates are removed and the remaining epithelial cells are then incubated with an antibody composition containing antibodies specific for CD24 and CD49f or CD24 and CD14. After formation of conjugates between the epithelial cells and the antibodies specific for CD24 and CD49f or CD24 and CD14, the mouse mammary stem and the luminal-restricted CFC cells can be differentially isolated.
    Type: Application
    Filed: June 6, 2007
    Publication date: February 7, 2008
    Inventors: John Stingl, Connie Eaves
  • Publication number: 20060281137
    Abstract: The present invention relates to an improved method that permits the differential isolation of mouse mammary stem cells and colony forming cells (CFCs). The method involves depletion of non-epithelial cells from freshly dissociated mouse mammary tissue by incubation with an antibody composition containing antibodies specific for CD45, Ter119, CD35 and optionally CD140a. After formation of conjugates between the non-epithelial mammary cells and the antibodies specific for CD45, Ter119, CD35 and optionally CD140a, the cell conjugates are removed and the remaining epithelial cells are then incubated with an antibody composition containing antibodies specific for CD24 and CD49f. After formation of conjugates between the epithelial cells and the antibodies specific for CD24 and CD49f, the mouse mammary stem and the luminal-restricted CFC cells can be differentially isolated. The invention also relates to kits for carrying out this method and to the cell preparations prepared by this method.
    Type: Application
    Filed: June 7, 2006
    Publication date: December 14, 2006
    Inventors: John Stingl, Connie Eaves